ABUS Past Earnings image   This ABUS past earnings page last updated 11/10/2022
ABUS Past Earnings
PeriodPast Earnings DateGAAP
Q3 202211/9/2022-0.120
Q2 20228/4/2022-0.100
Q1 20225/5/2022-0.110
Q4 20213/3/2022-0.150
Q3 202111/4/2021-0.240
Q2 20218/5/2021-0.230
Q1 20215/5/2021-0.210
Q4 20203/4/2021-0.230
Q3 202011/5/2020-0.270
Q2 20208/7/2020-0.250
Q1 20205/11/2020-0.250
Q4 20193/5/2020-0.460
Q3 201911/6/2019-0.730
Q2 20198/5/2019-0.460
Q1 20195/6/2019-0.470
Q4 20183/7/2019-0.37
Q3 201811/7/2018-0.3
Q2 20188/2/2018-0.44
Q1 20185/3/2018-0.36
Q4 20173/14/2018-0.35
Q3 201711/2/2017-0.17
Q2 20178/3/2017-0.28
Q1 20175/4/2017-0.29
Q4 20163/21/2017-0.38
Q3 201611/3/2016-0.31
Q2 20168/4/2016-0.35
Q1 20165/4/2016-0.19
Q4 20153/9/2016-0.07
Q3 201511/5/2015-0.31
Q2 20158/5/2015-0.2
Q1 20155/6/2015-0.36
Q4 20143/9/2015-0.27
Q3 201411/14/2014-0.39
Q2 20148/13/2014-0.31
Q1 20145/14/2014-0.93
Q4 20133/6/2014-0.100
Q3 201311/13/2013-0.420
Q2 20138/12/2013-0.220
Q1 20135/14/2013-0.18
Q4 20123/27/20132.81
Q3 201211/13/2012-0.25
ABUS Past Revenue
PeriodPast Earnings DateGAAP
Q3 202211/9/20220.01B
Q2 20228/4/20220.01B
Q1 20225/5/20220.01B
Q4 20213/3/20220.00B
Q3 202111/4/20210.00B
Q2 20218/5/20210.00B
Q1 20215/5/20210.00B
Q4 20203/4/20210.00B
Q3 202011/5/20200.00B
Q2 20208/7/20200.00B
Q1 20205/11/20200.00B
Q4 20193/5/20200.00B
Q3 201911/6/20190.00B
Q2 20198/5/20190.00B
Q1 20195/6/20190.00B
Q4 20183/7/20191.60M
Q3 201811/7/20181.60M
Q2 20188/2/20181.20M
Q1 20185/3/20181.40M
Q4 20173/14/20182.50M
Q3 201711/2/20176.90M
Q2 20178/3/20171.00M
Q1 20175/4/2017200000
Q4 20163/21/2017-0.20M
Q3 201611/3/2016700000
Q2 20168/4/2016300000
Q1 20165/4/2016600000
Q4 20153/9/201612.70M
Q3 201511/5/20154.10M
Q2 20158/5/20153.40M
Q1 20155/6/20154.70M
Q4 20143/9/20154.40M
Q3 201411/14/20144.40M
Q2 20148/13/20141.96M
Q1 20145/14/20144.91M
Q4 20133/6/20140.00B
Q3 201311/13/20130.00B
Q2 20138/12/20130.00B
Q1 20135/14/20130.00B
Q4 20123/27/20133.89M
Q3 201211/13/20123.05B
Quotes delayed 20 minutes

Email EnvelopeFree ABUS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Arbutus Biopharma (ABUS) is categorized under the Miscellaneous sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

ACHR Past Earnings
ACN Past Earnings
ADNT Past Earnings
ADTH Past Earnings
AFMD Past Earnings
ALIT Past Earnings
ALLE Past Earnings
AMPS Past Earnings
APTV Past Earnings
ARGO Past Earnings

ABUS Past Earnings Q&A

What was the best and worst ABUS past earnings results?
For Arbutus Biopharma, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?

✔️Accepted answer: The highest ABUS past earnings result in our data set was 2.81/share posted in Q4 2012, while the lowest was in Q1 2014 when ABUS posted -0.93/share.

  Suggested answer: The biggest top line earnings performance — aka revenue — quarter was in Q3 2012 when ABUS reported 3.05B in revenue, while the quarter with the lowest revenue in our data set was Q4 2016 at -0.20M of revenue.

  Suggested answer: There are 41 ABUS past earnings results in our data set.

On this page we presented the ABUS past earnings date information for Arbutus Biopharma. Reviewing that ABUS Past Earnings for the company, we see that the highest past earnings result in our data set was in Q4 2012, when ABUS posted gaap of 2.81/share. Meanwhile the lowest ABUS past earnings result was in Q1 2014, when ABUS posted gaap of -0.93/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q3 2012 when ABUS reported 3.05B in revenue, while the smallest revenue quarter was Q4 2016 when ABUS reported -0.20M in revenue.

Any self directed investor doing their due diligence on ABUS or any other given stock can benefit from researching all of the Arbutus Biopharma past earnings — and here, we present each quarter's result all together on one page for easy comparison. Studying this information can help when projecting future earnings, as well as determining whether the past earnings trajectory justifies the current stock value. That's why we bring you PastEarnings.com to make it easy for investors to investigate Arbutus Biopharma past earnings, or the past earnings information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for ABUS. Thanks for visiting, and the next time you need to research ABUS past earnings or those of another stock, we hope you'll think of our site, as your go-to past earnings research resource of choice.

Recommended: ETFs Holding AMSWA, CASA Options Chain, Top Ten Hedge Funds Holding AM.

 

ABUS Past Earnings | www.PastEarnings.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in PastEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.